Ebene Cybercity, Mauritius, June 11, 2026 (GLOBE NEWSWIRE) -- IUX has published a new article titled “5 ETF Risks to Understand During Volatile Markets,” examining several factors that may influence ETF performance during periods of heightened market uncertainty.
Collaboration leverages Gemini Enterprise to onboard engineers up to three times fasterAMSTERDAM, June 11, 2026 /PRNewswire/ -- Google Cloud today announced a collaboration with Randstad...
PARIS, June 11, 2026 (GLOBE NEWSWIRE) -- Proof of Pitch returned to the Louvre Palace on June 2 and 3 for its fourth edition, and two startups left Paris as winners. ReplyCorp took the General Track, and Parthenon won the Canton Track after live pitches in front of one of the strongest investor juries in Web3.
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL
From living longer to living free, people across Asia prioritize health and financial self-sufficiency to pursue independence and avoid burdening loved onesHONG KONG, June...
From living longer to living free, people across Asia prioritize health and financial self-sufficiency to pursue independence and avoid burdening loved onesHONG KONG, June...
LONG BEACH, Calif. and TORONTO, June 10, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. (“Glass House” or the “Company”) (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX:GHBWF) announced today that it has filed a short form base shelf prospectus (the “Shelf Prospectus”) dated June 10, 2026 with the securities regulatory authorities in all provinces and territories of Canada. The Shelf Prospectus replaces the Company’s prior short form base shelf prospectus, which was set to expire on June 17, 2026.
MONACO, June 10, 2026 (GLOBE NEWSWIRE) -- Crypto market news is turning toward AlphaPepe after the project submitted its CoinGecko listing as launch preparations continue to move forward. The presale has now crossed $1.49 million in total capital raised, Stage 17 is live at $0.01877, and holder growth has passed 9,400 while AlphaSwap demo traction and audit completion continue to support the project’s pre-listing profile.
DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 47,619,048 shares of its common stock at a public offering price of $1.05 per share. The aggregate gross proceeds from this offering are expected to be $50 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte. The closing of the offering is expected to occur on or about June 12, 2026, subject to the satisfaction of customary closing conditions. In addition, Humacyte has granted the underwriters an option for a period of 30 days to purchase up to an additional 7,142,857 shares of Humacyte’s common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being sold by Humacyte.